14,994 Shares of ARK Genomic Revolution ETF $ARKG Bought by Vigilare Wealth Management

Vigilare Wealth Management acquired a new position in shares of ARK Genomic Revolution ETF (BATS:ARKG) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 14,994 shares of the company’s stock, valued at approximately $813,000.

Several other hedge funds have also added to or reduced their stakes in the stock. Global View Capital Management LLC lifted its stake in ARK Genomic Revolution ETF by 59.0% in the third quarter. Global View Capital Management LLC now owns 41,424 shares of the company’s stock valued at $2,246,000 after purchasing an additional 15,366 shares during the last quarter. D.A. Davidson & CO. bought a new position in ARK Genomic Revolution ETF during the third quarter valued at $3,000,000. Oppenheimer & Co. Inc. bought a new position in ARK Genomic Revolution ETF during the third quarter valued at $1,627,000. Park Avenue Securities LLC purchased a new stake in ARK Genomic Revolution ETF in the third quarter worth $336,000. Finally, Flagship Harbor Advisors LLC purchased a new stake in ARK Genomic Revolution ETF in the third quarter worth $229,000.

ARK Genomic Revolution ETF Stock Performance

Shares of ARKG opened at $51.40 on Monday. The stock’s fifty day moving average price is $49.92 and its two-hundred day moving average price is $37.37. ARK Genomic Revolution ETF has a 1 year low of $24.60 and a 1 year high of $58.83.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.